Skip to content
Sign in
Venture capitalBacked 1 network startup

EFung Capital

Shenzhen life-science investor (since 2012) backing drug developers with phase 2/3 assets and device makers; backed Pleryon Therapeutics.

Shenzhen, China
Ticket
—Not published
Assets under management
—
Founded
2007
Stages
Series Ato Series B and later
Network startups backed
1
Co-investors
4most often with Kaitai Capital

How they invest

Life sciences: drug developers with phase 2/3 assets and device makers (Chipscreen, Ascentage, Centrexion). Network deal: Pleryon Therapeutics (Pre-A and Series A).

Stage and ticket

Series A and Series B and later.

Geography

China and global.

What makes them say yes

  • Clinical-stage asset (ideally phase 2/3)
  • China development/commercial angle
  • Strong IP and clinical data

Red flags

  • Preclinical-only programmes (inference from phase 2/3 focus)
  • Non-life-science

Sectors

  • Biotech & life sciences

Stages

  • Series A
  • Series B and later

Geographies

  • China
  • Global

How to approach

Approach founder Jinqiao Zhu or CSO Weimin Xiao with clinical data; Pleryon (network peer) can introduce.

Partners

  • Jinqiao ZhuFounder
  • Weimin XiaoPartner and CSO

Portfolio

1 network startup · no other company

Pleryon Pre-A (2022) and Series A (2025): follow-on support for a clinical-stage polymer therapeutics company.

Gaps in the portfolio

  • No network device maker in portfolio
  • No network nephrology asset

Network startups

  • Pleryon TherapeuticsSWC 2026 Finalist

    HKUST polymer-therapeutics platform entering the clinic in dry eye, with osteoarthritis and aesthetics as follow-on indications.

    China · Biotech & life sciences

Network startups that fit

4 analysed

KAIST spin-off developing PEGylated bilirubin BX-001N to prevent acute kidney injury after cardiac surgery, now in phase 2a in Korea.

Acute-kidney-injury drug with phase 1 done and phase 2a under way, at Series A: a clinical-stage asset approaching EFung's phase 2 sweet spot.

55%confidence

Evidence from the records

  • “drug developers with phase 2/3 assets”
  • “Drug for acute kidney injury”
  • “phase 2a under way in Korea”
Intro path
Pleryon Therapeutics (EFung portfolio)
First step
Send phase 1 data and the phase 2a design to EFung's CSO.

FDA-cleared low-cost automated peritoneal dialysis cycler, built in a DRAP-approved Pakistani factory, preparing first US patients.

At-home peritoneal dialysis with FDA 510(k) clearance and a DRAP-approved factory: device maker with regulatory validation, at seed.

40%confidence

Evidence from the records

  • “At-home peritoneal dialysis”
  • “FDA 510(k) clearance K243371”
First step
Pitch an Asia manufacturing/commercial partnership.

3D-printed biodegradable MediChip implant delivering chemotherapy locally at the tumour site, now in colorectal cancer trials in the UAE.

Oncology local drug delivery in clinical trials in the UAE with an $8M+ pre-Series A: clinical-stage drug-device combination.

40%confidence

Evidence from the records

  • “Oncology – local drug delivery”
  • “MediChip in clinical trials for colorectal cancer in the UAE”
First step
Share trial readouts and China development plan.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Co-investors

Most often with Kaitai Capital, Lapam Capital, and Zero2IPO

Sources

  1. 1seedtable.com/investors/efung-capital
  2. 2nature.com/articles/d43747-020-00514-5

Profile compiled from public sources. Unknown fields are left empty rather than estimated.